Get to know our clinical trials
Phase 1b dose-escalation clinical trial of OMTX705, an antibody-drug conjugate directed against fibroblast activation protein in combination with gemcitabine/nab-paclitaxel and tislelizumab
EL OBJETIVO DE ESTE ENSAYO ES COMPROBAR SI UN NUEVO MEDICAMENTO EN INVESTIGACIÓN, EL OMTX705, ES SEGURO Y BIEN TOLERADO CUANDO SE USA JUNTO CON OTROS DOS MEDICAMENTOS EXISTENTES: POR UN LADO LA GEMCITABINA (GEMZAR®) JUNTO A NAB-PACLITAXEL (ABRAXANE®) (GEMCITABINA Y NAB-PACLITAXEL SE ADMINISTRAN JUNTOS COMO PARTE DE UN ESQUEMA DE TRATAMIENTO COMBINADO) Y TISLELIZUMAB (TEVIMBRA®), ASÍ COMO DETERMINAR LA DOSIS MÁS ADECUADA DE ESTOS MEDICAMENTOS PARA UTILIZARLA EN FUTUROS ENSAYOS Y SEGUIR CON EL DESARROLLO CLÍNICO DEL OMTX705.
Technical Summary
- PHASE 1B DOSE-ESCALATION CLINICAL TRIAL OF OMTX705, AN ANTIBODY-DRUG CONJUGATE DIRECTED AGAINST FIBROBLAST ACTIVATION PROTEIN (FAP), IN COMBINATION WITH GEMCITABINE/NAB-PACLITAXEL AND TISLELIZUMAB, IN PATIENTS WITH ADVANCED-STAGE OR METASTATIC PANCREATIC ADENOCARCINOMA.
- Code EudraCT: 2025-521872-69
- Protocol number: OMTX705-006
- Promoter: Oncomatryx Biopharm S.L.
- Molecule/Drug: OMTX705
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.